- Must have hormone-refractory prostate cancer, defined as an increasing PSA by >= 3 ng/ml from androgen-blockade nadir, or new measurable or evaluable lesion on imaging studies, after treatment with orchiectomy, luteinizing hormone-releasing hormone (LHRH) agonist, antiandrogen or diethylstilbestrol (DES)